AlzeCure Pharma AB, a Swedish pharmaceutical company developing treatments for nervous system disorders, has appointed Cecilia Wadell, MScPharm, Ph.D., as Head of Development, effective August 20, 2025. The appointment represents a strategic strengthening of the company's clinical development capabilities as it advances multiple drug candidates targeting Alzheimer's disease and pain conditions.
Leadership Transition and Organizational Structure
Wadell will join AlzeCure's management team and lead the clinical development organization, taking over responsibilities from Dr. Märta Segerdahl, who will continue to focus on her role as Chief Medical Officer. This organizational restructuring allows for specialized leadership in both clinical development and medical affairs as the company expands its pipeline activities.
"I look forward to the strengthening of our development organization that Cecilia's appointment will bring. Cecilia has extensive experience in all phases of drug development and many years of experience in leadership roles," said Märta Segerdahl, CMO.
Extensive Industry Experience
Wadell brings more than 25 years of pharmaceutical industry experience, having held senior positions at both major pharmaceutical companies and smaller biotech organizations. Her career spans roles at AstraZeneca, Wilson Therapeutics, Medivir, and World Wide Clinical Trials, providing her with comprehensive experience across different organizational structures and development approaches.
Martin Jönsson, CEO of AlzeCure, emphasized the strategic value of Wadell's diverse background: "We are very pleased to have Cecilia join the team. Her extensive experience in running clinical development projects, including orphan drug projects, and building R&D organizations, will strengthen our clinical capacity as we now have several projects in or on their way to clinical development."
Strategic Timing and Pipeline Development
The appointment comes at a critical juncture for AlzeCure as the company advances multiple projects through clinical development phases. Jönsson noted that Wadell's experience from both large pharmaceutical companies and smaller biotech companies, as well as from the contract research organization (CRO) side, will be particularly valuable for clinical project development, business development activities, and partnership discussions.
"Her experience from both large pharmaceutical companies and smaller biotech companies, as well as from the CRO side, will also be of great importance for the development work with our clinical projects, business development work and partnership discussions," Jönsson stated.
Focus on Nervous System Disorders
AlzeCure Pharma specializes in developing candidate drugs for diseases affecting the nervous system, with particular emphasis on Alzheimer's disease and pain management. The company's focus on these therapeutic areas positions it within critical unmet medical need segments where new treatment options are urgently required.
Wadell expressed enthusiasm about joining the organization during this pivotal period: "I am excited to join AlzeCure at such an exciting time in the company's development. I hope to use my many years of clinical experience in clinical drug development to take AlzeCure's drug candidates to the next level."
